Radiopharm Theranostics Limited (RADX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $2.62. The rating moved from Strong Oversold to Oversold on July 31, 2026.

• Public ratingOversold (as of August 19, 2026)
• Last close$2.62
• Last changeMoved from Strong Oversold to Oversold on July 31, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

Radiopharm Theranostics Limited (RADX) is an early-stage radiopharmaceutical/theranostics developer with sector tailwinds from growing demand for oncology diagnostics and targeted radiopharma. The company’s near-term outlook is driven by upcoming clinical and regulatory milestones, potential partnership or manufacturing agreements, and its financing runway. Key challenges include high clinical and regulatory risk, likely dilution needs, manufacturing complexity, and limited public financial transparency — outcomes will hinge on milestone execution, partner traction, and clearer reimbursement signals.

Key factors

• Niche radiopharmaceutical / theranostics focus positions the company to benefit from rising diagnostic and targeted therapy demand in oncology
• Sector tailwinds for diagnostics and oncology screening increase potential commercial addressable market
• Early-stage development profile — clinical readouts and regulatory milestones are material catalysts
• Limited public financial disclosures and likely dependence on external financing increase short-term uncertainty
• Potential for partnerships or CDMO/CRO relationships to de‑risk commercialization and manufacturing
• Broader risk‑on market tone and constructive macro backdrop may modestly support small-cap biotech names in the near term

Risks

• Clinical and regulatory failure or delays for lead assets
• Short cash runway and need for dilutive financing, especially at current market cap/price
• Reimbursement and payer coverage uncertainty for radiopharmaceutical therapies and diagnostics
• Manufacturing, scale-up and cold-chain distribution challenges unique to radiopharmaceuticals
• Competition from larger established diagnostics and radiopharma players
• Low liquidity and high share‑price volatility typical of small-cap biotech/theranostics companies
• Macro risk: rising rates or sudden risk-off sentiment could sharply reduce access to capital

Latest MarketMoodz coverage

• Radiopharm Theranostics Eyes Pivotal Path After RAD101 Interim Results2026-03-24

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.